Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
about
Trends in HIV surveillance data in the EU/EEA, 2005 to 2014: new HIV diagnoses still increasing in men who have sex with men.The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment.Evaluating the Impact of a HIV Low-Risk Express Care Task-Shifting Program: A Case Study of the Targeted Learning RoadmapGlobal HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialDemographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialPulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialTransmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialQuality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialKidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialBaseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialAssessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialMeeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach
P2860
Q31029701-DE9911BF-0FE6-470A-86B2-0C0FF62A26F8Q33745361-91EB6F3C-4C39-49D6-96D6-8AD68C962D1DQ33922137-97BEF385-145B-4D57-A228-182FC8162E0BQ35124860-E42F9F75-61E3-4B80-BD8F-555D54677AE0Q35124897-44BAE143-E938-40FC-B5A0-9611D6444ED4Q35124901-97DF6CDF-D535-45FC-B889-6E4B9DA4EDE1Q35124905-6B85C3C6-C48C-4BF1-B1E1-1016FE0889E1Q35124913-AECA3563-F138-4245-AA00-E4F746553ED9Q35124919-F670A6DC-A40F-40A0-9F6B-CD0D7E4F03CBQ35124927-9192158B-B131-4CB6-8A7B-58FB719F3CF1Q35124931-9DA17CB8-E595-49D0-A283-2D614A518669Q35124936-93A5F12C-DF85-40D4-B484-A58E83FE4C01Q35124939-B64B7968-141C-4948-80B4-980E790E7720Q35124958-C6201D1C-57FD-49BD-9D2E-920B0F6A3D55Q35124970-E8266A59-2230-451B-A50B-7595E2DC260BQ35216275-5A30CC49-4F64-498F-A5B6-85D7B8E02B6EQ38675771-A9311222-ED76-4EFF-A256-463B0F9BA22BQ41466494-69C158DB-E99F-4202-948D-1B24099B7B75Q41466517-6CD9BC8E-174A-47FE-8150-DE7AD2949259Q52655906-438BBC72-1CC4-4373-A86A-39C118BB3C87Q57175535-D770234B-A9BF-4590-A89C-AF42F69786E8
P2860
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Why START? Reflections that le ...... long-term strategic HIV trial.
@ast
Why START? Reflections that le ...... long-term strategic HIV trial.
@en
type
label
Why START? Reflections that le ...... long-term strategic HIV trial.
@ast
Why START? Reflections that le ...... long-term strategic HIV trial.
@en
prefLabel
Why START? Reflections that le ...... long-term strategic HIV trial.
@ast
Why START? Reflections that le ...... long-term strategic HIV trial.
@en
P2093
P2860
P50
P356
P1433
P1476
Why START? Reflections that le ...... long-term strategic HIV trial.
@en
P2093
Abdel Babiker
Fred Gordin
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group
James D Neaton
Jean-Michel Molina
Sean Emery
P2860
P356
10.1111/HIV.12227
P478
16 Suppl 1
P577
2015-04-01T00:00:00Z